Saturday - September 25, 2021
University of Texas's MD Anderson Cancer: Combination Therapy Achieves High Rates of Response for Patients With Acute Lymphoblastic Leukemia
May 19, 2021
HOUSTON, Texas, May 19 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release:

A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with front-li . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

What's your
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products